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from decubitus ulcers of patients in this geriatric
institution. Before 1999, no MRSA was detected in
residents of this facility, and only a few sporadic
cases were found in patients admitted to HUSD.
Five different clonal types of MRSA were detected
among the 17 patients of the geriatric institution,
with the five patients who had been admitted to
HUSD since 1999 each being infected by a
different clonal type of MRSA. Since all these
clones had been documented previously in
patients admitted to HUSD, it seems reasonable
to conclude that these patients acquired MRSA
strains during their hospitalisation period. The
fact that the other 12 patients had not been
hospitalised previously in HUSD suggests that
these MRSA clones may have spread subse-
quently between different patients within the
geriatric institution. The high rate of MRSA found
highlights the importance of epidemiological
analysis in controlling the dissemination of MRSA
in chronic care facilities, as in tertiary hospitals.
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A B S T R A C T
The combination of vancomycin and b-lactams is
often considered synergistic and has been recom-
mended for the treatment of glycopeptide-inter-
mediate Staphylococcus aureus (GISA) infections. In
this study, the combination of vancomycin or
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teicoplanin with different b-lactams was tested.
When using NaCl 4%w ⁄ v, for better expression of
heterogeneous resistance to b-lactams, with a
longer (48-h) incubation period and a higher
(107 CFU ⁄mL) inoculum, the association of vanco-
mycin with b-lactams was antagonistic. However,
a synergistic effect was observed for teicoplanin
under the same conditions.
Keywords b-Lactams, GISA, glycopeptides, suscepti-
bility testing, Staphylococcus aureus
Original Submission: 16 February 2003; Revised
Submission: 11 September 2003; Accepted: 30
September 2003
Clin Microbiol Infect 2004; 10: 342–345
10.1111/j.1198-743X.2004.00856.x
Glycopeptide-intermediate Staphylococcus aureus
(GISA) strains have been isolated in our hospital
for more than 10 years [1,2], and similar strains
are now reported worldwide [3]. These strains,
similar to strain Mu3 [3], show low-level resist-
ance to vancomycin and teicoplanin, with MICs
not exceeding 3 and 16 mg ⁄L, respectively, on
Mueller-Hinton (MH) agar with a standard ino-
culum, and MICs of 6–8 or 8–32 mg ⁄L, respect-
ively, when tested on Brain Heart Infusion (BHI)
agar with a higher inoculum [3]. Most import-
antly, all these strains display heterogeneous
resistance to vancomycin (and teicoplanin), with
colonies growing on 8–16 mg ⁄L of vancomycin,
in contrast to 2–4 mg ⁄L for fully susceptible
strains [3]. Very few strains worldwide are fully
resistant to vancomycin, with an MIC of 8 mg ⁄L
for a strain (Mu50) isolated in Japan by K.
Hiramatsu, and MICs of > 128 mg ⁄L for two
recent strains isolated in the USA which carry
the vanA gene [4]. The clinical impact of GISA has
not been established; reported clinical failures can
be attributed to low vancomycin levels or inap-
propriate associations [5]. It has been demonstra-
ted that, with appropriate vancomycin dosage
and serum level determination, the failure rate for
GISA is similar to the failure rate with fully-
susceptible strains [6].
Confusing results concerning the association of
vancomycin or teicoplanin with b-lactams have
been reported, in that synergy or antagonism has
been observed with the same bacteria and the
same antibiotic associations, but with different
testing procedures [7,8]. In most, if not all of these
studies, conditions were not optimal for the
expression of heterogeneous resistance to b-lac-
tams. The influence of salt on the MIC of vanco-
mycin alone or in association with b-lactams has
been rarely but clearly reported [9]. In view of
these previous results, the aim of this study was
to determine the activity of vancomycin or tei-
coplanin in combination with different b-lactams.
Fourteen GISA strains isolated in France during
1992–2000 were tested in comparison to the proto-
type Japanese strains Mu50 and Mu3, two methi-
cillin-resistant S. aureus (MRSA) strains and one
methicillin-sensitive S. aureus strain susceptible to
glycopeptides, and the susceptible reference strain
ATCC 25923. Strains Lim2 and 98141 were
obtained from M. C. Ploy and N. El Solh (Institut
Pasteur, Paris, France), respectively; the 12 other
strains were isolated at the Saint-Joseph Hospital,
Paris. MICs of either vancomycin or teicoplanin
were determined by the Etest method, with or
without NaCl 4% w ⁄v, on MH agar and BHI agar
with an inoculum of 0.5 · McFarland standard.
Plates were incubated for 48 h at 37 C in air. MICs
were also determined under the same conditions in
the presence of cefotaxime 8 mg ⁄L and oxacillin
8 mg ⁄L. Alternatively, MICs of oxacillin, amoxy-
cillin–clavulanate (with a fixed clavulanic acid
concentration of 2 mg ⁄L) and cefotaxime were
determined under the same conditions on plates
containing vancomycin or teicoplanin at 2, 4, 6 or
8 mg ⁄L. All tests were performed at least three
times.
The interaction between vancomycin or teicopl-
anin and b-lactams was also studied on BHI agar,
with or without NaCl 4% w ⁄v, with various
b-lactam disks on plates containing vancomycin
or teicoplanin at 2, 4, 6 or 8 mg ⁄L.
Strains were considered to be GISA if the
vancomycin MIC was ‡ 4 mg ⁄L or the teicopla-
nin MIC was ‡ 8 mg ⁄L and the population ana-
lysis profile was similar to that of strain Mu3,
with colonies growing at vancomycin ‡ 6 mg ⁄L,
in contrast to < 4 mg ⁄L for fully susceptible
strains.
The results showed that the MICs of oxacillin,
amoxycillin–clavulanate and cefotaxime for all
GISA strains were ‡ 32 mg ⁄L when tested on
MH agar or BHI agar containing NaCl 4% w ⁄ v
(data not shown). The comparative MICs of vanco-
mycin or teicoplanin on BHI agar in the presence or
absence of NaCl 4% w ⁄ v are shown in Table 1.
When tested on MH agar, the MICs were 0.5–1.5
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dilutions lower (data not shown). In the presence of
NaCl, the MICs of vancomycin for the French GISA
isolates were 0.5–2 dilutions higher, and the MICs
of teicoplanin were 0.5–2 dilutions lower. For
strains Mu3 and Mu50, there was no increase
and, eventually, a 0.5–1 dilution decrease in the
MIC of vancomycin. For the glycopeptide-suscept-
ible strains, the shift in the MIC was minimal.
Fig. 1 shows the results of the interaction of
vancomycin with cefotaxime for strain Mu3 in the
absence (A) or presence (B) of NaCl 4% w ⁄ v. A
moderate to strong antagonism was observed
according to the test conditions. Similar results
were obtained with all the French GISA isolates.
In the presence of cefotaxime (8 mg ⁄L) in the
agar, the MICs of vancomycin were 2–6 mg ⁄L in
the absence of NaCl and 3–8 mg ⁄L with NaCl 4%
w ⁄ v in the agar. For teicoplanin, the MICs were
6–16 mg ⁄L (no NaCl) or 2–4 mg ⁄L (NaCl 4%
w ⁄ v), respectively.
For strain Mu50, addition of NaCl did not
improve expression of the heterogeneous methi-
cillin resistance (Mu50 is a mecA-positive strain,
but is penicillinase-negative). In contrast to other
GISA strains, the association of vancomycin with
b-lactams was antagonistic in the absence of
NaCl, but not in the presence of NaCl. For
teicoplanin, the association with b-lactams was
synergistic; this synergy was enhanced in the
presence of NaCl.
As indicated by Hiramatsu [3], all GISA strains
have undergone multiple small adjustments in
their cell-wall metabolism, but they are not
identical. GISA strains have a prolonged genera-
tion rate, grow as small colonies, need multiple
nutrients and are more or less unstable. Incuba-
tion for at least 48 h is required before final
interpretation of MIC results [3–5,7,10]. Numer-
ous previous studies have demonstrated clearly
that the addition of NaCl 2–5% w ⁄ v is necessary
for the expression of resistance to b-lactams in
many heterogeneous MRSA strains. It is unclear
why this procedure is used normally only for the
detection of resistance and not for MIC determi-
nations. When tested correctly, MRSA strains are
Table 1. MICs of vancomycin and teicoplanin obtained by






VA BHI VA BHI +NaCl TEC BHI TEC BHI + NaCl
1 ATCC 25923 3 3 3 1
2 MU3 4 3 24 8
3 MU50 12 12 32 16
4 LIM2 6 12 24 12
5 12909 6 8 6 6
6 JL77 4 8 16 6
7 BER 4 12 12 8
8 98141 6 12 16 8
9 GIO 4 8 12 6
10 BAC 6 12 16 8
11 PRE 6 8 16 6
12 CAD 4 8 16 8
13 ROD 6 8 12 6
14 COQ 6 8 12 8
15 BER 4 8 8 6
16 MER 6 8 12 6
17 COQ 6 8 12 6
18 RM 13042 3 3 3 2
19 RM 13062 3 3 3 1.5
20 RM 13089 3 3 3 2
Strains 4–17, 14 GISA isolates from France; strains 18–20, two MRSA and one
methicillin-sensitive S. aureus susceptible to glycopeptides; VA, vancomycin; TEC,
teicoplanin; BHI, brain heart infusion.
(a) (b)
Fig. 1. MIC of cefotaxime for strain
Mu3 on BHI agar containing vanco-
mycin 2 mg ⁄L: (a) without NaCl; (b)
with NaCl 4% w ⁄ v. In the absence
of NaCl (a), there is clear antagon-
ism over a limited concentration
range 0.12–2 mg ⁄L. However, the
presence of a few colonies at con-
centrations > 2 mg ⁄L corresponds to
what is usually observed when test-
ing b-lactams on MRSA strains at
sub-optimal conditions. In the pres-
ence of NaCl 4% w ⁄ v (b) there is
clear antagonism for cefotaxime con-
centrations of ‡ 32 mg ⁄L
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always resistant to all b-lactams without any
exception.
The reason why NaCl increases resistance to
vancomycin, as described previously [9], is not
known, nor is the reason for the decrease in the
MIC of teicoplanin, which to our knowledge has
never been reported previously. Antagonism
between b-lactams and vancomycin is very clear
in the presence of NaCl 4%w ⁄ v (Fig. 1b), and this
is particularly true for strain Mu3. For some other
strains, the persistance of a few colonies within
the b-lactam inhibition zone indicates that at least
part of the population is not inhibited by high
concentrations of b-lactams in the presence of
vancomycin. Moreover, because of the short half-
life of most b-lactams, it is anticipated that only
low b-lactam levels are present to interact with
glycopeptides for quite a long period. However,
at high vancomycin concentrations, and for a very
limited MIC range (0.5–1 mg ⁄L), the interaction
between vancomycin and b-lactams can be con-
sidered as synergistic.
In contrast to vancomycin, the interaction
between teicoplanin and b-lactams is more often
synergistic, as has been demonstrated previ-
ously for teicoplanin-resistant isolates of Staphy-
lococcus epidermidis [11]; in the presence of NaCl
there is enhanced synergy, depending on the
precise concentration of the b-lactam (data not
shown).
The precise clinical significance and reasons for
these results are unknown, but it can be conclu-
ded that vancomycin should not be used in
association with b-lactams for the treatment of
GISA infections.
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